A feasibility trial of gamma sensory flicker for patients with prodromal Alzheimer's disease

被引:66
|
作者
He, Qiliang [1 ,2 ]
Colon-Motas, Kay M. [3 ]
Pybus, Alyssa F. [1 ,2 ,4 ,5 ]
Piendel, Lydia [3 ]
Seppa, Jonna K. [3 ]
Walker, Margaret L. [3 ,6 ]
Manzanares, Cecelia M. [3 ,6 ]
Qiu, Deqiang [1 ,2 ,6 ,7 ]
Miocinovic, Svjetlana [1 ,2 ,3 ,6 ]
Wood, Levi B. [1 ,2 ,4 ,5 ]
Levey, Allan I. [3 ,6 ]
Lah, James J. [3 ,6 ]
Singer, Annabelle C. [1 ,2 ]
机构
[1] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, 313 Ferst Dr,UAWSuite 3105, Atlanta, GA 30332 USA
[2] Emory Univ, Atlanta, GA 30332 USA
[3] Emory Univ, Emory Brain Hlth Ctr, Dept Neurol, Atlanta, GA USA
[4] Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA USA
[5] Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA USA
[6] Emory Univ, Goizueta Alzheimer Dis Res Ctr, Atlanta, GA USA
[7] Emory Univ, Dept Radiol & Imaging Sci, Sch Med, Atlanta, GA USA
关键词
amyloid beta; cytokines; default mode network; electrophysiology; feasibility trial; gamma stimulation; neural stimulation; prodromal Alzheimer's disease; sensory stimulation; PHASE-I TRIAL; STEM-CELLS; BRAIN; STIMULATION; MICROGLIA;
D O I
10.1002/trc2.12178
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction We and collaborators discovered that flickering lights and sound at gamma frequency (40 Hz) reduce Alzheimer's disease (AD) pathology and alter immune cells and signaling in mice. To determine the feasibility of this intervention in humans we tested the safety, tolerability, and daily adherence to extended audiovisual gamma flicker stimulation. Methods Ten patients with mild cognitive impairment due to underlying AD received 1-hour daily gamma flicker using audiovisual stimulation for 4 or 8 weeks at home with a delayed start design. Results Gamma flicker was safe, tolerable, and adherable. Participants' neural activity entrained to stimulation. Magnetic resonance imaging and cerebral spinal fluid proteomics show preliminary evidence that prolonged flicker affects neural networks and immune factors in the nervous system. Discussion These findings show that prolonged gamma sensory flicker is safe, tolerable, and feasible with preliminary indications of immune and network effects, supporting further study of gamma stimulation in AD.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Gamma Sensory Flicker for Patients with Prodromal Alzheimer's Disease: A Phase I Trial
    He, Qiliang
    Colon-Motas, Kay
    Pybus, Alyssa
    Pendel, Lydia
    Seppa, Jonna
    Walker, Margaret
    Manzanares, Cecelia
    Qui, Deqiang
    Miocinovic, Svjetlana
    Wood, Levi
    Levey, Allan
    Lah, James
    Singer, Annabelle C.
    ANNALS OF NEUROLOGY, 2020, 88 : S96 - S96
  • [2] Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease
    Egan, Michael F.
    Kost, James
    Voss, Tiffini
    Mukai, Yuki
    Aisen, Paul S.
    Cummings, Jeffrey L.
    Tariot, Pierre N.
    Vellas, Bruno
    van Dyck, Christopher H.
    Boada, Merce
    Zhang, Ying
    Li, Wen
    Furtek, Christine
    Mahoney, Erin
    Mozley, Lyn Harper
    Mo, Yi
    Sur, Cyrille
    Michelson, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (15): : 1408 - 1420
  • [3] THE CHALLENGE OF TREATING PRODROMAL ALZHEIMER'S DISEASE PATIENTS
    Gauthier, Serge
    NEUROBIOLOGY OF AGING, 2012, 33 : S12 - S13
  • [4] Genistein effect on cognition in prodromal Alzheimer's disease patients. The GENIAL clinical trial
    Vina, Jose
    Escudero, Joaquin
    Baquero, Miquel
    Cebrian, Monica
    Antonio Carbonell-Asins, Juan
    Enrique Munoz, Jose
    Satorres, Encarnacion
    Carlos Melendez, Juan
    Ferrer-Rebolleda, Jose
    del Puig Cozar-Santiago, Ma
    Manuel Santabarbara-Gomez, Jose
    Jove, Mariona
    Pamplona, Reinald
    Jose Tarazona-Santabalbina, Francisco
    Borras, Consuelo
    ALZHEIMERS RESEARCH & THERAPY, 2022, 14 (01)
  • [5] A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
    Susanne Ostrowitzki
    Robert A. Lasser
    Ernest Dorflinger
    Philip Scheltens
    Frederik Barkhof
    Tania Nikolcheva
    Elizabeth Ashford
    Sylvie Retout
    Carsten Hofmann
    Paul Delmar
    Gregory Klein
    Mirjana Andjelkovic
    Bruno Dubois
    Mercè Boada
    Kaj Blennow
    Luca Santarelli
    Paulo Fontoura
    Alzheimer's Research & Therapy, 9
  • [6] Genistein effect on cognition in prodromal Alzheimer’s disease patients. The GENIAL clinical trial
    José Viña
    Joaquín Escudero
    Miquel Baquero
    Mónica Cebrián
    Juan Antonio Carbonell-Asíns
    José Enrique Muñoz
    Encarnación Satorres
    Juan Carlos Meléndez
    José Ferrer-Rebolleda
    Mª del Puig Cózar-Santiago
    Jose Manuel Santabárbara-Gómez
    Mariona Jové
    Reinald Pamplona
    Francisco José Tarazona-Santabalbina
    Consuelo Borrás
    Alzheimer's Research & Therapy, 14
  • [7] A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease
    Ostrowitzki, Susanne
    Lasser, Robert A.
    Dorflinger, Ernest
    Scheltens, Philip
    Barkhof, Frederik
    Nikolcheva, Tania
    Ashford, Elizabeth
    Retout, Sylvie
    Hofmann, Carsten
    Delmar, Paul
    Klein, Gregory
    Andjelkovic, Mirjana
    Dubois, Bruno
    Boada, Merce
    Blennow, Kaj
    Santarelli, Luca
    Fontoura, Paulo
    ALZHEIMERS RESEARCH & THERAPY, 2017, 9
  • [8] Detection of Prodromal Alzheimer's Disease
    Mortimer, James A.
    Petersen, Ronald C.
    ANNALS OF NEUROLOGY, 2008, 64 (05) : 479 - 480
  • [9] Verubecestat for Prodromal Alzheimer's Disease
    Li, Shaomin
    Liu, Lei
    Selkoe, Dennis
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04): : 388 - 388
  • [10] Dissection of prodromal Alzheimer's disease
    Sheng, Can
    Huang, Yue
    Han, Ying
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2018, 23 : 1272 - 1291